Transformative Diagnostics


bioref

Next-Generation Therapies & Vaccines

Addressing large, unmet global markets with innovative proprietary products More »

Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »

Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

News & Events

more news »
Nov. 9, 2018

OPKO Health Reports Third Quarter 2018 Financial Results more »

Nov. 8, 2018

OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018 more »

Sep. 14, 2018

OPKO Confirms Resumption of Common Stock Trading on Nasdaq more »

Investors

read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.

 

 

FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »